Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China
NCT ID: NCT02458651
Last Updated: 2018-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1378 participants
OBSERVATIONAL
2015-06-26
2018-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
NCT05872763
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
NCT06617390
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer
NCT03505515
A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma
NCT05984017
Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer
NCT05979623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tier 1 and North
Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
No intervention
No intervention administered in this study
Tier 1 and South
Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
No intervention
No intervention administered in this study
Tier 2 and Middle
Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
No intervention
No intervention administered in this study
Tier 2 and North
Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
No intervention
No intervention administered in this study
Tier 2 and South Eastern
Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
No intervention
No intervention administered in this study
Tier 2 and South Western
Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
No intervention
No intervention administered in this study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention administered in this study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received at least one anti-cancer treatment targeting unresectable Stage IIIB or IV NSCLC in the study site after study initiation
* Radiographic evidence of disease
Exclusion Criteria
* Participation in any anti-cancer, regimen-specified clinical study of first-line treatment for unresectable Stage IIIB or IV NSCLC.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, , China
the First Hospital of Jilin University
Changchun, , China
Sichuan Provincial Cancer Hospital
Chengdu, , China
Third Affiliated Hospital of Third Military Medical University
Chongqing, , China
Fujian Cancer Hospital
Fuzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
The First Affiliate Hospital of Guangxi Medical University
Nanning, , China
Zhongshan Hospital Fudan University
Shanghai, , China
Shanghai First People's Hospital
Shanghai, , China
Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center
Wuhan, , China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YO29443
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.